Desentum
  • Home
  • Technology
  • Company
  • News
  • Contact
  • Suomi
Select Page

Desentum’s UPSIT study with birch pollen allergy treatment DM-101PX approved by Paul-Ehrlich-Institut in Germany

by kati.sallinen@desentum.fi | Nov 6, 2026 | News

The German regulatory authority Paul-Ehrlich-Institut has approved Desentum’s clinical trial application for a clinical study with DM-101PX, an investigational immunotherapeutic treatment for birch pollen allergy. The study will be carried out at Fraunhofer ITEM in...

Desentum raises €28 million to develop safer, more effective allergen immunotherapy

by kati.sallinen@desentum.fi | Oct 12, 2026 | News

Desentum, a Finnish clinical-stage biopharmaceutical company, has closed an oversubscribed €28 million equity round to advance its allergy immunotherapy programmes. The round, arranged by Finnish investment firm Springvest, is one of the largest ever raised by a...

New peer-reviewed publication on Desentum’s investigational birch pollen allergen immunotherapy DM-101PX

by kati.sallinen@desentum.fi | Sep 14, 2026 | News

A scientific paper reporting the Phase 1 clinical trial results of DM-101PX has been published in the renowned journal Clinical & Experimental Allergy by Desentum together with clinical and academic collaborators. The randomised, placebo-controlled trial tested a...

Desentum to present at the 2026 EAACI annual congress in Istanbul this week

by kati.sallinen@desentum.fi | Jun 9, 2026 | News

Two abstracts related to Desentum’s product development projects have been accepted for presentation at the annual congress of the European Academy of Allergy and Clinical Immunology (EAACI) taking place in Istanbul, Türkiye, on Jun 12–15, 2026. The abstracts focus on...

Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland

by kati.sallinen@desentum.fi | Apr 27, 2026 | News

Desentum’s 18 M€ share issue organised by the Finnish growth equity company Springvest marks the largest public share issue* ever conducted in Finland by an unlisted growth company. The company is advancing a novel allergen immunotherapy platform that has the...
« Older Entries

Viimeisimmät artikkelit

  • Desentum’s UPSIT study with birch pollen allergy treatment DM-101PX approved by Paul-Ehrlich-Institut in Germany
  • Desentum raises €28 million to develop safer, more effective allergen immunotherapy
  • New peer-reviewed publication on Desentum’s investigational birch pollen allergen immunotherapy DM-101PX
  • Desentum to present at the 2026 EAACI annual congress in Istanbul this week
  • Desentum’s 18 M€ share issue from private investors and family offices breaks a record for unlisted growth companies in Finland

Viimeisimmät kommentit

No comments to show.

DESENTUM OY

Tekniikantie 14, 02150 Espoo, Finland
info@desentum.fi

  • Follow
  • Follow

© Desentum Oy

Privacy policy
​​Cookie settings
Website: Räikee Oy

© Desentum Oy

Tietosuojaseloste
​​Evästeasetukset
Nettisivut: Räikee Oy